Meeting
2012 ASCO Annual Meeting
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
Authors
Ian D. Davis
Austin Health, Heidelberg, Australia
Ian D. Davis , Val Gebski , Mark D. Chatfield , Peter S. Grimison , George Kannourakis , Amy L Boland , Jennifer Thompson , Martin R. Stockler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
ACTRN12609000643279
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS4681)
DOI
10.1200/jco.2012.30.15_suppl.tps4681
Abstract #
TPS4681
Poster Bd #
14H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma.
First Author: Hailiang Zhang
Poster
2021 ASCO Annual Meeting
Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).
First Author: Robert J. Motzer
Poster
2018 Genitourinary Cancers Symposium
Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
First Author: Paul L. de Souza
Poster
2018 Genitourinary Cancers Symposium
Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.
First Author: Darren R. Feldman